According to a Bloomberg News report, Reckitt Benckiser Group Plc would be launching a review on the options of its pharmaceutical unit. The maker of medical products such as Nurofen painkillers and Durex condoms had been influenced by analysts who had urged the company to exit from the pharmaceutical business.
In a statement, Reckitt said it would be updating its investors next year. The company had also increased its full-year revenue guidance, prompting share price increase by 5.1%.
Reckitt Chief Executive Officer Rakesh Kapoor said by phone, "We've always said it's a fantastic business, but it's not core to the company. I've said that several months after the entry of generics we will confirm the resiliency of the film business and the impact of generics. We are now in that phase. Nothing is ruled out."
The company said its annual revenue would gain 6% at least. The percentage included acquisitions and divestments, but would not include any pertinent financial data from its pharmaceutical unit.
Join the Conversation